Amplia Receives R&D Tax Rebate Totalling $4.78 Million
Amplia Therapeutics Limited (ASX: ATX) has received A$4,778,235.52 through the Australian Government’s Research and Development Tax Incentive for the financial year ended 31 March 2026.
The Research and Development Tax Incentive encourages eligible Australian businesses to undertake research and development activities by providing a refundable tax offset for qualifying expenditure.
Amplia’s rebate relates to expenditure on research and development activities associated with its FAK inhibitor programs, narmafotinib (AMP945) and AMP886. These activities are primarily related to the Company’s ongoing clinical trials of narmafotinib in patients with advanced pancreatic cancer.
The funds will support:
further progression of the ACCENT and AMPLICITY clinical trials of narmafotinib
the ACCENT-MINI Trial
the PRROSE Study
the Lilly combination study
additional supporting research and development activities